Management of Venous Thromboembolism in Patients Receiving Immunomodulatory Agents
Release Date: May 07, 2020
Expiration Date: May 07, 2021
Expected time to complete this activity as designed: 15 minutes
There are no fees for participating in or receiving credit for this online activity.
Patients with myeloma have an increased risk of venous thromboembolism (VTE). In this activity, Dr. Kumar explains the contributing factors to VTE, how these findings relate to risk stratification, and what system is the most useful in assessing VTE risk in myeloma. He will also describe the best options for when VTE prophylaxis is warranted.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Summarize the prevalence and impact of venous thromboembolism (VTE) in multiple myeloma
- Identify therapeutic strategies for prophylaxis in NDMM patients who may be at risk for VTEs
- Outline clinical expert recommendations for prophylaxis of VTEs in patients with multiple myeloma
Management of Venous Thromboembolism in Patients Receiving Immunomodulatory Agents – Shaji K. Kumar, MD
Instructions for Participation and Credit
This activity is eligible for credit through May 07, 2021. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Shaji K. Kumar, MD
Professor of Medicine
Clinical Research Office
Mayo Clinic Cancer Center
Dr. Shaji Kumar received his medical degree from All India Institute of Medical Sciences in New Delhi, India. His postdoctoral training included a residency in internal medicine from the All India Institute of Medical Sciences, followed by a residency in internal medicine and a fellowship in hematology/oncology at the Mayo Graduate School of Medicine in Rochester, Minnesota. Dr. Kumar is a Consultant in the Division of Hematology and Professor of Medicine at Mayo Clinic Cancer Center in Rochester, Minnesota. He serves as Medical Director for the Mayo Clinic Cancer Center Clinical Research Office and Vice Chair for Research in the Department of Medicine, Mayo Clinic.
Dr. Kumar serves as Co-Chair of the NCI Myeloma Steering Committee and as Chair of the NCCN Multiple Myeloma Guidelines Panel. His research focuses on the development of novel drugs and drug combinations for the treatment of myeloma. His laboratory focuses on understanding the role of bone marrow microenvironment in the development and progression of myeloma.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-20-018-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Shaji Kumar has received honoraria related to speakers’ bureau and formal advisory activities from AbbVie Inc., Adaptive Biotechnologies, Celgene Corporation, Janssen Pharmaceuticals, Inc., Kite Pharma, AstraZeneca (formerly MedImmune, LLC), Oncopeptides AB, and Takeda Oncology. He has received research support for Mayo Clinic Cancer Center clinical trials from AbbVie, Celgene, Janssen, F. Hoffmann-La Roche Ltd, Kite, AstraZeneca, Merck & Co., Inc., Novartis AG, Sanofi, and Takeda.
Andrew Bowser, contributing author, has disclosed no relevant financial relationships.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Andrea Mathis, Project Manager, Wilma Guerra, Program Director, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at firstname.lastname@example.org
Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.
©2020 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.